Skip to main content
Top
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Multiple Sclerosis | Research

Exploring physicians’ prescribing behavior in patients with multiple sclerosis in Saudi Arabia: a sequential explanatory mixed-methods

Authors: Hussain Abdulrahman Al-Omar, Nada Alsowaida, Lama Aldosari, Ahmed Mayet, Reem Bunyan, Mohammed Aljumah

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

Multiple sclerosis (MS) is the most common disabling neurological disease in young adults worldwide with majority of patients manifest symptoms between 20 and 40 years of age. The aims of this study are to explore physicians’ perspectives, views, and behaviors in diagnosing and treating patients with MS in Saudi Arabia and investigate the prescribing pattern of disease-modifying therapies (DMTs).

Methods

A sequential explanatory mixed-method approach was used to achieve the study objectives. The quantitative arm of the study consisted of patient data extracted from the Saudi MS registry from 2015 to 2018. The qualitative study consisted of in-depth semi-structured interviews with physicians using a validated interview topic guide comprising 28 open-ended questions.

Results

We extracted data of 2,507 patients from 20 different hospitals across Saudi Arabia. Patients’ mean age was 34 ± 10 years; two-thirds (n = 1,668) were female. 92% (n = 2,292) had relapsing-remitting multiple sclerosis, and 5% (n = 126) had secondary-progressive multiple sclerosis. In general, patients with MS received at least one drug as the DMT or DMTs and corticosteroids for those with relapse. Qualitatively, nine physicians agreed to participate in the interviews. Of them, five (55%) were male and four were female from different regions. Thematic analysis yielded three main themes: practice, views, and challenges.

Conclusions

The prevalence of MS in Saudi Arabia is raising but is still much lower than that reported in the Gulf region. A national MS guideline is needed to streamline diagnosis and treatment criteria, avoid any delay in treatment, and guide physicians who provide care for patients with MS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Garcia-Dominguez JM, Maurino J, Martinez-Gines ML, Carmona O, Caminero AB, Medrano N, et al. Economic burden of multiple sclerosis in a population with low physical disability. BMC Public Health. 2019;19(1):609.CrossRefPubMedPubMedCentral Garcia-Dominguez JM, Maurino J, Martinez-Gines ML, Carmona O, Caminero AB, Medrano N, et al. Economic burden of multiple sclerosis in a population with low physical disability. BMC Public Health. 2019;19(1):609.CrossRefPubMedPubMedCentral
4.
go back to reference Bebo BF Jr, Fox RJ, Lee K, Utz U, Thompson AJ. Landscape of MS patient cohorts and registries: recommendations for maximizing impact. Mult Scler. 2018;24(5):579–86.CrossRefPubMed Bebo BF Jr, Fox RJ, Lee K, Utz U, Thompson AJ. Landscape of MS patient cohorts and registries: recommendations for maximizing impact. Mult Scler. 2018;24(5):579–86.CrossRefPubMed
5.
go back to reference Paul S, Brown A, Hughes AJ. Cognitive Assessment of individuals with multiple sclerosis in the Arab World: a systematic review. Neuropsychol Rev. 2019;29(3):259–69.CrossRefPubMed Paul S, Brown A, Hughes AJ. Cognitive Assessment of individuals with multiple sclerosis in the Arab World: a systematic review. Neuropsychol Rev. 2019;29(3):259–69.CrossRefPubMed
6.
go back to reference Wade BJ. Spatial analysis of global prevalence of multiple sclerosis suggests need for an updated prevalence scale. Mult Scler Int. 2014;2014:124578.PubMedPubMedCentral Wade BJ. Spatial analysis of global prevalence of multiple sclerosis suggests need for an updated prevalence scale. Mult Scler Int. 2014;2014:124578.PubMedPubMedCentral
7.
go back to reference AlJumah M, Bunyan R, Al Otaibi H, Al Towaijri G, Karim A, Al Malik Y, et al. Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study. BMC Neurol. 2020;20(1):49.CrossRefPubMedPubMedCentral AlJumah M, Bunyan R, Al Otaibi H, Al Towaijri G, Karim A, Al Malik Y, et al. Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study. BMC Neurol. 2020;20(1):49.CrossRefPubMedPubMedCentral
8.
go back to reference Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. 2015;3(7):545–55.CrossRefPubMedPubMedCentral Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. 2015;3(7):545–55.CrossRefPubMedPubMedCentral
10.
go back to reference Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, Chitnis T. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019;35:119–27.CrossRefPubMed Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, Chitnis T. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019;35:119–27.CrossRefPubMed
12.
go back to reference Bunyan R, Al Towaijri G, Al Otaibi H, Kareem A, Algahtani H, Al Mejally M, et al. Prevalence of Pediatric Onset multiple sclerosis in Saudi Arabia. Mult Scler Int. 2021;2021:4226141.PubMedPubMedCentral Bunyan R, Al Towaijri G, Al Otaibi H, Kareem A, Algahtani H, Al Mejally M, et al. Prevalence of Pediatric Onset multiple sclerosis in Saudi Arabia. Mult Scler Int. 2021;2021:4226141.PubMedPubMedCentral
13.
go back to reference Al-Jumah M, Bunyan R, Al Otaibi H, Cupler E, Ishak S, Shami S et al. The Saudi Arabian National Multiple Sclerosis Registry (NMSR): Initial Results Saudi MS Registry Study Group* (P2.390). Neurology. 2018;90(15 Supplement):P2.390. Al-Jumah M, Bunyan R, Al Otaibi H, Cupler E, Ishak S, Shami S et al. The Saudi Arabian National Multiple Sclerosis Registry (NMSR): Initial Results Saudi MS Registry Study Group* (P2.390). Neurology. 2018;90(15 Supplement):P2.390.
14.
go back to reference Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77–101.CrossRef Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77–101.CrossRef
15.
go back to reference Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536–41.CrossRefPubMedPubMedCentral Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536–41.CrossRefPubMedPubMedCentral
16.
go back to reference Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120.CrossRefPubMed Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120.CrossRefPubMed
17.
go back to reference Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–88.CrossRefPubMed Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–88.CrossRefPubMed
18.
go back to reference Mescheriakova JY, Wong YYM, Runia TF, Jafari N, Samijn JP et al. Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome. JAMA Neurol. 2018;75(11):1392-8. Mescheriakova JY, Wong YYM, Runia TF, Jafari N, Samijn JP et al. Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome. JAMA Neurol. 2018;75(11):1392-8.
19.
go back to reference Yamout B, Alroughani R, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research in multiple sclerosis (MENACTRIMS). Curr Med Res Opin. 2015;31(7):1349–61.CrossRefPubMed Yamout B, Alroughani R, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research in multiple sclerosis (MENACTRIMS). Curr Med Res Opin. 2015;31(7):1349–61.CrossRefPubMed
20.
go back to reference Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:17562864211019574.CrossRefPubMedPubMedCentral Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:17562864211019574.CrossRefPubMedPubMedCentral
21.
go back to reference Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Maurer M, et al. Multiple sclerosis therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648.CrossRefPubMedPubMedCentral Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Maurer M, et al. Multiple sclerosis therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648.CrossRefPubMedPubMedCentral
22.
go back to reference O’Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology. 2014;83(1):78–86.CrossRefPubMedPubMedCentral O’Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology. 2014;83(1):78–86.CrossRefPubMedPubMedCentral
23.
go back to reference Callegari I, Derfuss T, Galli E. Update on treatment in multiple sclerosis. Presse Med. 2021;50(2):104068.CrossRefPubMed Callegari I, Derfuss T, Galli E. Update on treatment in multiple sclerosis. Presse Med. 2021;50(2):104068.CrossRefPubMed
24.
go back to reference Klinsing S, Yalachkov Y, Foerch C. Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools. Eur J Neurol. 2022;29(4):1100–5.CrossRefPubMed Klinsing S, Yalachkov Y, Foerch C. Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools. Eur J Neurol. 2022;29(4):1100–5.CrossRefPubMed
25.
go back to reference Diaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: an update. Mult Scler Relat Disord. 2019;30:215–24.CrossRefPubMed Diaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: an update. Mult Scler Relat Disord. 2019;30:215–24.CrossRefPubMed
26.
go back to reference Iacobaeus E, Arrambide G, Amato MP, Derfuss T, Vukusic S, Hemmer B, et al. Aggressive multiple sclerosis (1): towards a definition of the phenotype. Mult Scler. 2020;26(9):1352458520925369.CrossRefPubMed Iacobaeus E, Arrambide G, Amato MP, Derfuss T, Vukusic S, Hemmer B, et al. Aggressive multiple sclerosis (1): towards a definition of the phenotype. Mult Scler. 2020;26(9):1352458520925369.CrossRefPubMed
27.
go back to reference Lee Mortensen G, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. Patient Prefer Adherence. 2017;11:1789–96.CrossRefPubMedPubMedCentral Lee Mortensen G, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. Patient Prefer Adherence. 2017;11:1789–96.CrossRefPubMedPubMedCentral
28.
go back to reference Peloquin S, Schmierer K, Leist TP, Oh J, Murray S, Lazure P. Challenges in multiple sclerosis care: results from an international mixed-methods study. Mult Scler Relat Disord. 2021;50:102854.CrossRefPubMed Peloquin S, Schmierer K, Leist TP, Oh J, Murray S, Lazure P. Challenges in multiple sclerosis care: results from an international mixed-methods study. Mult Scler Relat Disord. 2021;50:102854.CrossRefPubMed
29.
go back to reference Simonsen CS, Flemmen HO, Broch L, Brunborg C, Berg-Hansen P, Moen SM, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of Future Disease Activity over 1 and 2 years in a norwegian Population-Based Registry. Front Neurol. 2021;12:693017.CrossRefPubMedPubMedCentral Simonsen CS, Flemmen HO, Broch L, Brunborg C, Berg-Hansen P, Moen SM, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of Future Disease Activity over 1 and 2 years in a norwegian Population-Based Registry. Front Neurol. 2021;12:693017.CrossRefPubMedPubMedCentral
Metadata
Title
Exploring physicians’ prescribing behavior in patients with multiple sclerosis in Saudi Arabia: a sequential explanatory mixed-methods
Authors
Hussain Abdulrahman Al-Omar
Nada Alsowaida
Lama Aldosari
Ahmed Mayet
Reem Bunyan
Mohammed Aljumah
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03184-9

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue